Trial Profile
Effect of Renal Impairment on the Effectiveness and Safety of Two GLP-1 Receptor Agonists, Exenatide, and Liraglutide in Patients with Type 2 Diabetes
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 29 Jul 2015
Price :
$35
*
At a glance
- Drugs Exenatide (Primary) ; Liraglutide (Primary)
- Indications Diabetic nephropathies; Type 2 diabetes mellitus
- Focus Therapeutic Use
- 29 Jul 2015 New trial record
- 09 Jun 2015 Results presented at the 75th Annual Scientific Sessions of the American Diabetes Association.